Athanasios Motsenigos Email & Phone Number

Responsible for an operating budget of € 55 m, a brand team of 5 and the coordination of more than 100 Sales Representatives, 15 First Line Sales Managers and 4 Regional Sales Managers.Significant Achievements•1st position in the J1 Anti-infectives Market in Greece and 6th between all GSK subsidiaries in Europe•Increase sales to € 51 m and growth 5% vs LY•Launch successfully in 2008 nine new line extensions of marketed antibiotics which will offer every year more than € 3.5… Show more Responsible for an operating budget of € 55 m, a brand team of 5 and the coordination of more than 100 Sales Representatives, 15 First Line Sales Managers and 4 Regional Sales Managers.Significant Achievements•1st position in the J1 Anti-infectives Market in Greece and 6th between all GSK subsidiaries in Europe•Increase sales to € 51 m and growth 5% vs LY•Launch successfully in 2008 nine new line extensions of marketed antibiotics which will offer every year more than € 3.5 m. profit and maintain a substantial growth in the anti-infectives market•Obtain for the 3rd consecutive year double digit growth and net annual sales of € 4 m. in the Urology market with the brand Dutasteride (Avodart), despite the -30% price cut of the product. •In 2006 forged strategic relationship with the Japanese pharmaceutical industry Tedek Meiji, thus resulting in the licence in the oral antibiotic Cefditoren pivoxil and achieved sales of € 7 m. in two years (National GSK award for our team). Show less

Significant Achievements•Increase sales growth in the Hospital market over 50% •Achieve sales of € 9 m (+200% vs LY) and reposition all injectable antibiotics•GSK Greece is selling more than 60% of the total Timentin European sales •Increase the market share of all GSK antibiotics in the Primary Care and Hospital market to 23%. (actual annual growth +30%)•Establish a network all over Greece, of Paediatricians, Infectiologists and Microbiologists with common interest on… Show more Significant Achievements•Increase sales growth in the Hospital market over 50% •Achieve sales of € 9 m (+200% vs LY) and reposition all injectable antibiotics•GSK Greece is selling more than 60% of the total Timentin European sales •Increase the market share of all GSK antibiotics in the Primary Care and Hospital market to 23%. (actual annual growth +30%)•Establish a network all over Greece, of Paediatricians, Infectiologists and Microbiologists with common interest on infectious diseases and organise monthly meetings through videoconference. This network after two years created the Paediatric Infectious Disease Society of GreeceLaunche in the intranasal market the unique line extension of Flixonase nasule drops from Australia. Since its launch the portfolio achieves yearly sales of € 0,5 m. without any extra cost. Show less